This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to his portfolio right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 chemicals business Croda International (LSE:CRDA) has been increasing its dividend annually for each of the last 32 years. And I think there’s more to come.

The company’s share price is lower than it was five years ago, but I think the long-term prospects for the business look good. To me, this looks like a stock to buy while it’s on sale.

What does Croda do?

Just under 90% of Croda’s revenue comes from two industries. The first is consumer care (52%) and the second is life sciences (36%).

In consumer care, the company makes the chemicals that give things like skincare products their specific properties. So this might be reducing the appearance of wrinkles, or improving skin tone.

In life sciences, Croda’s chemicals go into drug delivery systems. In short, this is what enables drugs – including Pfizer’s Covid-19 vaccine – to target specific parts of the body. 

Importantly, the dividend aristocrat isn’t a manufacturer of generic chemicals – its products are highly specialised. In my view, this makes it a much more attractive business to consider investing in.

Why invest?

Generic chemicals companies sell their products at whatever the market rate is. The only kind of competitive advantage comes from keeping its own costs down, which is hard in an inflationary environment.

By contrast, Croda’s differentiated products give it the ability to set its own prices. And the high switching costs for customers enable the company to pass on the effects of inflation. 

Its personal care chemicals are protected by patents, preventing duplication by competitors. And its drug delivery products are specified in approval documents making them virtually irreplaceable.

In short, Croda’s competitors can’t emulate its products and customers can’t replace them. That’s a powerful combination that puts the business in an extremely strong position.

Why now?

Croda’s share price is almost 30% lower than it was a year ago. The main reason is that demand has fallen away sharply in the life sciences division as the Covid-19 pandemic has subsided. 

Management said recently that it couldn’t say when things would recover. With interest rates above 5%, the opportunity cost of waiting is a risk investors ought to take seriously.

I see the share price as an opportunity though. The business might be more cyclical than investors imagined when the stock hit an all-time-high in 2021, but I think it’s an extremely high-quality firm. 

It might be difficult to say exactly when things will pick up for Croda, but I don’t think there’s much question that they will. With a long-term perspective, I’m looking to buy the stock now and wait.

Rising payouts

A 2.25% dividend yield might not seem like a lot. But Croda’s ability to increase its shareholder distributions, even in an extremely difficult environment, is outstanding.

This is why the company’s achieved Dividend Aristocrat status. And its growth hasn’t been trivial either – over the last decade, payments to shareholders have increased by an average of 5% a year.

If I’m right about Croda, the share price won’t be this low indefinitely. So I’m looking to buy the stock for my portfolio before the market starts to get more optimistic.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stephen Wright has positions in Pfizer. The Motley Fool UK has recommended Croda International Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man changing battery on electric bicycle
Investing Articles

Suddenly my FTSE income shares are giving me growth too – including this 9% yielder!

Harvey Jones loves his FTSE 100 dividend income shares but was disappointed by the lack of growth. Now it looks…

Read more »

Investing Articles

This FTSE AIM travel business could absolutely skyrocket in 2025

FTSE AIM stock Jet2 appears to be a bargain in plain sight. I’m desperately searching for reasons not to buy…

Read more »

Investing Articles

This Bank of England news makes me fear for Lloyds and its share price!

Warnings of weak economic growth, resurgent inflation, and falling interest rates pose a toxic cocktail for Lloyds' share price.

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »